[O6] Oral Session 6　Lung Cancer / Thoracic Cancer 1（Molecularly-targeted therapy EGFR, ALK）
【E】

[O6-2] ORCHARD osimertinib + savolitinib interim analysis: PhII platform study in EGFRm NSCLC after progression on osimertinib

^○Isamu Okamoto¹, Helena Yu², Helen Ambrose³, Christina Baik⁴, Byoung Chul Cho⁵, Emiliano Cocco⁶, Sarah B Goldberg⁷, Jonathan Goldman⁸, Silvija Kraljevic³, Adrianus Johannes De Langen⁹, Zofia Piotrowska¹⁰, Michael Pluta¹¹, Julie Maidment¹², Noemí Reguart¹³, Jonathan W Riess¹⁴, Xiuning Le¹⁵ (1.Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 2.Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA, 3.Early Oncology, Oncology R&D, AstraZeneca, Cambridge, UK, 4.Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, USA, 5.Division of Medical Oncology, Yonsei Cancer Center, Seoul, Republic of Korea, 6.Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA, 7.Yale School of Medicine, New Haven, CT, USA, 8.UCLA, Los Angeles, CA, USA, 9.Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands, 10.Department of Medicine, Massachusetts General Hospital, Boston, MA, USA, 11.Early Oncology, Oncology Statistics, AstraZeneca, Cambridge, UK, 12.Patient Safety Oncology, Chief Medical Office, AstraZeneca, Cambridge, UK, 13.Department of Medical Oncology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain, 14.Internal Medicine – Haematology/Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA, 15.Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA)